Publicaciones en colaboración con investigadores/as de Hospital Universitario de Guadalajara (31)

2024

  1. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain

    Annals of Pharmacotherapy, Vol. 58, Núm. 2, pp. 140-147

  2. HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality

    Frontiers in Immunology, Vol. 15

  3. IL-15 boosts activated HBV core-specific CD8+ progenitor cells via metabolic rebalancing in persistent HBV infection

    iScience, Vol. 27, Núm. 1

2023

  1. A new year and a new roadmap for the journal in challenging times

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 115, Núm. 1, pp. 1-2

  2. Elevación persistente de Gamma-Glutamil-Transferasa

    Colección de casos clínicos cerrados de la Facultad de Medicina y Ciencias de la Salud - Universidad de Alcalá (2021-2022) (Servicio de Publicaciones), pp. 25-35

2022

  1. Current challenges in the functional cure of HBe-antigen negative chronic hepatitis B

    Revista Espanola de Enfermedades Digestivas, Vol. 114, pp. 441-444

  2. Letter: the probability to predict HBV-specific CD8+ cell response derived from HLA-A2+ may not foresee the functional cure well in Asian off-therapy cohort—authors' reply

    Alimentary Pharmacology and Therapeutics

  3. Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B

    Alimentary Pharmacology and Therapeutics, Vol. 55, Núm. 12, pp. 1545-1559

2021

  1. Anti-pd-1/pd-l1 based combination immunotherapy to boost antigen-specific cd8+ t cell response in hepatocellular carcinoma

    Cancers, Vol. 13, Núm. 8

  2. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C

    Cells, Vol. 10, Núm. 3

2020

  1. Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history

    World Journal of Hepatology, Vol. 12, Núm. 10, pp. 754-765

2019

  1. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment

    World Journal of Gastroenterology, Vol. 25, Núm. 38, pp. 5883-5896

2018

  1. According to hepatitis C virus (HCV) infection stage, interleukin-7 plus 4-1BB triggering alone or combined with PD-1 blockade increases TRAF1low HCV-specific CD8+ cell reactivity

    Journal of Virology, Vol. 92, Núm. 2

  2. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 277-283

  3. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

    World Journal of Gastroenterology, Vol. 24, Núm. 17, pp. 1825-1838

2016

  1. Hepatitis aguda grave por sobreinfección por virus delta: Importancia diagnóstica de la biología molecular

    Acta Gastroenterologica Latinoamericana, Vol. 46, Núm. 1, pp. 35-37

  2. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis

    World Journal of Gastroenterology, Vol. 22, Núm. 28, pp. 6469-6483

2015

  1. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control

    World Journal of Gastroenterology, Vol. 21, Núm. 12, pp. 3480-3491

  2. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480

2014

  1. Adaptive immune response during hepatitis C virus infection

    World Journal of Gastroenterology, Vol. 20, Núm. 13, pp. 3418-3430